Study of BMN-270 at a dose of 6e13vg/kg in patients with severe haemophilia A
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2017
At a glance
- Drugs Valoctocogene-roxaparvovec (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- 09 Dec 2017 According to a BioMarin Pharmaceutical media release, this trial will enroll its first patient this month.
- 26 Oct 2017 According to a BioMarin Pharmaceutical media release, Clinical Trial Applications have also been approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for study protocol.
- 26 Oct 2017 According to a BioMarin Pharmaceutical media release, the company expects complete enrollment of the last patient by the end of 2018 and provide top-line Phase 3 data by the end of 2019.